Evidence map›Paper›PMID 38655474›Full record

ArticleRSC advances2024

ProteoMutaMetrics: machine learning approaches for solute carrier family 6 mutation pathogenicity prediction.

Jiahui Huang, Tanja Osthushenrich, Aidan MacNamara, Anders Mälarstig, Silvia Brocchetti, Samuel Bradberry, Lia Scarabottolo, Evandro Ferrada, Sergey Sosnin, Daniela Digles and 2 more

Abstract read
In one paragraph

Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jiahui HuangUniversity of Vienna, Department of Pharmaceutical Sciences Vienna Austria gerhard.f.ecker@univie.ac.at.ORCID https://orcid.org/0009-0000-7922-2084
Tanja OsthushenrichBayer AG, Division Pharmaceuticals, Biomedical Data Science II Wuppertal Germany.
Aidan MacNamaraBayer AG, Division Pharmaceuticals, Biomedical Data Science II Wuppertal Germany.
Anders MälarstigEmerging Science & Innovation, Pfizer Worldwide Research, Development and Medical Cambridge MA USA.
Silvia BrocchettiAxxam SpA Bresso Milan Italy.
Samuel BradberryAxxam SpA Bresso Milan Italy.
Lia ScarabottoloAxxam SpA Bresso Milan Italy.
Evandro FerradaCeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences Vienna Austria.
Sergey SosninUniversity of Vienna, Department of Pharmaceutical Sciences Vienna Austria gerhard.f.ecker@univie.ac.at.
Daniela DiglesUniversity of Vienna, Department of Pharmaceutical Sciences Vienna Austria gerhard.f.ecker@univie.ac.at.
Giulio Superti-FurgaCeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences Vienna Austria.
Gerhard F EckerUniversity of Vienna, Department of Pharmaceutical Sciences Vienna Austria gerhard.f.ecker@univie.ac.at.ORCID https://orcid.org/0000-0003-4209-6883

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The solute carrier transporter family 6 (SLC6) is of key interest for their critical role in the transport of small amino acids or amino acid-like molecules. Their dysfunction is strongly associated with human diseases such as including schizophrenia, depression, and Parkinson's disease. Linking single point mutations to disease may support insights into the structure-function relationship of these transporters. This work aimed to develop a computational model for predicting the potential pathogenic effect of single point mutations in the SLC6 family. Missense mutation data was retrieved from UniProt, LitVar, and ClinVar, covering multiple protein-coding transcripts. As encoding approach, amino acid descriptors were used to calculate the average sequence properties for both original and mutated sequences. In addition to the full-sequence calculation, the sequences were cut into twelve domains. The domains are defined according to the transmembrane domains of the SLC6 transporters to analyse the regions' contributions to the pathogenicity prediction. Subsequently, several classification models, namely Support Vector Machine (SVM), Logistic Regression (LR), Random Forest (RF), and Extreme Gradient Boosting (XGBoost) with the hyperparameters optimized through grid search were built. For estimation of model performance, repeated stratified k-fold cross-validation was used. The accuracy values of the generated models are in the range of 0.72 to 0.80. Analysis of feature importance indicates that mutations in distinct regions of SLC6 transporters are associated with an increased risk for pathogenicity. When applying the model on an independent validation set, the performance in accuracy dropped to averagely 0.6 with high precision but low sensitivity scores.

Identifiers

PMID38655474
PMCPMC11034476

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.